<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00982514</url>
  </required_header>
  <id_info>
    <org_study_id>ASP NOPHO 2008</org_study_id>
    <nct_id>NCT00982514</nct_id>
  </id_info>
  <brief_title>Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008</brief_title>
  <official_title>Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine the prevalence of venous thromboembolism in children with acute
      lymphoblastic leukaemia treated in accordance with NOPHO ALL-2008. The investigators will
      prospectively study clinical symptomatic thromboses, asymptomatic central line-associated
      thromboses, and infections.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evident thrombosis</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Asymptomatic central line-associated thrombosis</measure>
    <time_frame>33 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive blood culture</measure>
    <time_frame>33 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard dose asparaginase</arm_group_label>
    <description>Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced dose asparaginase</arm_group_label>
    <description>Children who receive reduced dose asparaginase according to NOPHO ALL 2008</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Oslo University Hospital, Department of Pediatrics
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukaemia,

          -  Age 1 year to 16 years old,

          -  Central line,

          -  Protocol NOPHO ALL 2008.

        Exclusion Criteria:

          -  Refusal of participation,

          -  Treated according to protocol other than NOPHO ALL 2008.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Ruud, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Ruud, MD PhD</last_name>
    <phone>+47 23074560</phone>
    <email>ellen.ruud@rikshospitalet.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tonje Reiersen, MD</last_name>
    <phone>+47 23070000</phone>
    <email>tonje.reiersen@rikshospitalet.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rikshospitalet, Dep of Pediatrics</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ellen Ruud, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.nopho.org</url>
    <description>The home page for NOPHO who is responsible for the ALL treatment protocol</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2009</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asparaginase</keyword>
  <keyword>thrombosis</keyword>
  <keyword>ALL</keyword>
  <keyword>central line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

